Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

被引：48

作者：

Assi, Tarek ^{[1
]}

Kattan, Joseph ^{[1
]}

Rassy, Elie ^{[1
,2
]}

Nassereddine, Hussein ^{[1
]}

Farhat, Fadi ^{[1
]}

Honore, Charles ^{[2
]}

Le Cesne, Axel ^{[2
]}

Adam, Julien ^{[2
]}

Mir, Olivier ^{[2
]}

机构：

[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, Beirut, Lebanon

[2] French Sarcoma Grp, Gustave Roussy Canc Campus, Villejuif, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷

关键词：

Liposarcoma; Soft tissue sarcoma; CDK4; MDM2; Palbociclib; Abemaciclib; Ribociclib; SOFT-TISSUE SARCOMA; PHASE-II; 1ST-LINE TREATMENT; SYNOVIAL SARCOMA; INHIBITOR; CANCER; DOXORUBICIN; ABEMACICLIB; PALBOCICLIB; EFFICACY;

D O I：

10.1016/j.critrevonc.2020.103029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.

引用

页数：6

共 50 条

[21] INHIBITION STUDIES OF TERPENE BASED NATURAL PRODUCTS WITH CYCLIN-DEPENDENT KINASE 4 (CDK4 MIMIC CDK2)
Ganatra, Sunil H.
Suchak, Amita S.
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2012, 3 (09): : 3196 - 3203
[22] The Cyclin D/Cyclin-dependent Kinase 4/6 Complex as a Target in the Treatment of Breast Cancer
Clark A.S.
DeMichele A.
Current Breast Cancer Reports, 2015, 7 (4) : 175 - 182
[23] Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data
Vidula, Neelima
Rugo, Hope S.
CLINICAL BREAST CANCER, 2016, 16 (01) : 8 - 17
[24] Targeting CDK4/6 pathways and beyond in breast cancer
Ribnikar, Domen
Volovat, Simona Ruxandra
Cardoso, Fatima
BREAST, 2019, 43 : 8 - 17
[25] Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment
Parylo, S.
Vennepureddy, A.
Dhar, V.
Patibandla, P.
Sokoloff, A.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (01) : 110 - 129
[26] Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review
Sharaf, Baha'
AlMasri, Rama
Abdel-Razeq, Nayef
Salama, Osama
Hamad, Ibrahim
Abunasser, Mahmoud
Abdel-Razeq, Hikmat
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2022, 15 : 5 - 10
[27] Synthesis and Biological Evaluation of Novel 99mTc-Labeled Palbociclib Derivatives Targeting Cyclin-Dependent Kinase 4/6 (CDK4/6) as Potential Cancer Imaging Agents
Song, Xiaoqing
Gan, Qianqian
Zhang, Xuran
Zhang, Junbo
MOLECULAR PHARMACEUTICS, 2019, 16 (10) : 4213 - 4222
[28] Concurrent Use of Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors with Palliative Radiotherapy for Metastatic Breast Cancer Patients: A Review of Toxicity
Sonmez, Ozlem
Tezcanli, Evrim
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2021, 36 (04): : 538 - 542
[29] Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors
Ettl, Johannes
BREAST CARE, 2019, 14 (02) : 86 - 92
[30] Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
Gomatou, Georgia
Trontzas, Ioannis
Ioannou, Stephanie
Drizou, Maria
Syrigos, Nikolaos
Kotteas, Elias
MOLECULAR BIOLOGY REPORTS, 2021, 48 (01) : 915 - 925

← 1 2 3 4 5 →